By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Tuesday, 17 Nov 2026
Donate to The Mirror
Masvingo Mirror
  • Local News
  • Politics
  • Business
  • Sports
  • Health
  • Travel
  • Agriculture
  • Opinion
  • More
    • Lifestyle
    • Technology
    • Education
    • Religion
    • Community
    • Crime
    • International
    • Zim Universities/College Research Projects
My News
Latest News
Fashion enthusiast seeks to open doors for local talent
Chiredzi Town Council acquires US$129k excavator
Runde RDC to dispose off 8 old vehicles
From a Tomato Garden, US$300 at Uni, Courts: Samantha Chidodo’s Triumph Over Child Marriage
War veterans to hold liberation songs symposium
Masvingo MirrorMasvingo Mirror
Font ResizerAa
  • Read History
  • Environment
  • Business
  • Politics
  • Finance
  • Technology
Search
  • Pages
    • Home
    • Blog Index
    • Contact Us
    • Search Page
    • 404 Page
  • Personalized
    • Read History
  • Categories
    • Business
    • Politics
    • Technology
    • Environment
    • Finance
Have an existing account? Sign In
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Health

Breakthrough in HIV Prevention: Lenacapavir Shows 100% Efficacy

mv_admin
Last updated: 27 July 2024 3:44 am
By
mv_admin
Share
9 Min Read
SHARE

CATHERINE MUROMBEDZI

HEALTH CORRESPONDENT

The International AIDS Conference (IAC) is the premier global platform to advance the HIV response. As the world’s largest 25th AIDS Conference on HIV and AIDS, in Munich, Germany took place 22 July to 26, it brought advocacy and human rights, scientists, policy makers, healthcare professionals, people living with HIV, funders, media and communities together. Since its start in 1985, the conference has served as an opportunity to strengthen policies and programmes that ensure an evidence-based response to HIV and related pandemics. With 10,000 participants from around the world attending in person, the conference shares breakthroughs.

The International Aids Society (IAS) President Sharon Lewin was pleased with the results of the PURPOSE 1 trial, which demonstrated 100% efficacy for HIV prevention in cisgender women through twice-yearly injectable lenacapavir. Lewin described the results as a “breakthrough advance with huge public health potential.”She emphasized that if approved and delivered rapidly, affordably, and equitably, this long-acting tool could help accelerate global progress in HIV prevention.”The data confirms that twice-yearly lenacapavir for HIV prevention is a breakthrough advance with huge public health potential.”If approved and delivered — rapidly, affordably, and equitably — to those who need or want it. This long-acting tool could help accelerate global progress in HIV prevention.”Lewin expressed gratitude to the clinical trial participants.

“We all owe a debt of gratitude to the thousands of young women in South Africa and Uganda who volunteered to be part of this study,” expressed Lewin.She looked forward to the results of PURPOSE 2.The PURPOSE 2 clinical trial is taking place in the United States, South Africa, Peru, Brazil, Argentina, Mexico, and Thailand. This trial is assessing the efficacy of lenacapavir for pre-exposure prophylaxis, prevention (PrEP) among cisgender men who have sex with men, transgender men, transgender women, and gender non-binary individuals who have sex with partners assigned male at birth.The PURPOSE 2 trial aims to evaluate the safety and efficacy of an investigational, twice-yearly injectable medicine, lenacapavir, to reduce the chance of getting HIV.

“We don’t have an HIV vaccine or cure yet, but we have the next best thing: a prevention medication that is 100% effective!” said Lewin.The adage so near, yet so far, for resource limited countries depending on grants and donations, the availability of the prevention jab could be a mirage.This novel prevention jab given twice a year could close the tap to new HIV infections. The Choice Agenda reported that 1.3 million were infected with HIV in 2023 globally.“Current new HIV infection of 1.3 million people annually, 2.4% translates to one infection in every 42 people. If the drug is to be given to 42 people to prevent 1 infection, then the price should come down,” noted the Choice Agenda.

Doctors, nurses turn mercenary
My Journey with MDR-TB: A Story of Resilience and Hope
0,2 million condoms used in Zvishavane in 2021
NAC targets remote Midlands communities with US$64k health, empowerment support

“A recent pricing analysis argues that lenacapavir can be mass-produced for US$63 to US$93 per person each year. It could further fall I’d massive mass production is reached to cost US$26 to US$40 per person annually.“Nonetheless, Gilead still encounters pushback over its pricing, which advocates argue has too often made it difficult for patients to access HIV treatments. At the same time, the company has been criticized for its patenting strategies — including a lawsuit with the US government over discovery work — that advocates say can delay licensing and, therefore, access to lower-cost generics. This helps explain why researchers have, periodically, examined production costs of different drugs with hope of highlighting dichotomies between manufacturing expenses and sales prices,” reported the Choice Agenda.

The argument made is that companies can charge less, widen access, and still make a profit for various medicines, such as those for treating weight loss, diabetes, hepatitis C, and tuberculosis, among others.Including formulation, vials, and profit margins, a generic injectable form of lenacapavir could be mass-produced for US$63 to US$93 per person each year. It could fall to US$26 to US$40 per person if mass production is pursued, according to the new analysis. The researchers noted these prices require voluntary licenses and competition between generic suppliers.“Gilead needs to allow generic lenacapavir prices under US$100 per person year.

The major donors will only agree on funding mass treatment programmes if we can achieve these low prices,” argued Andrew Hill, one of the co-authors of the new analysis and a senior visiting research fellow in the Department of Pharmacology and Therapeutics at the University of Liverpool.“If Gilead allows mass production of generic lenacapavir for under US$100 a year, we could soon have millions of people at high risk of HIV taking lenacapavir and not being infected.“Gilead has the potential to dramatically lower HIV infection rates worldwide. But if Gilead charges high prices and restricts access, the HIV epidemic will continue to rise,” said Hill.Speaking in Munich at the 25th AIDS Conference, Joyce Ouma, (27), of Kenya, who is a senior programmes officer at the Global Network of Young People Living with HIV, explained that a similar drug for those already infected would be welcome. “It is not an exaggeration to say that meeting the 2030 goal of ending new HIV transmissions hinges on Gilead ensuring people in the Global South have fair access to lenacapavir.

A twice-yearly injectable would be transformative for young people like me living with or at risk of HIV. It would allow people to live their lives freely without the daily task of taking pills which, for some people often living where HIV isn’t fully understood, still carries a sense of stigma that impacts our mental health and wellbeing.”A spokeswoman from Gilead wrote on their website that the company awaits additional information from Phase 3.“While the company awaits additional Phase 3 clinical trial data and the potential regulatory filings for HIV prevention administered twice-yearly, it is too early to state the price of lenacapavir for PrEP. Our pledge is to price our medicines to reflect the value they deliver to people, patients, healthcare systems and society. The selection of high-incidence, resource-limited countries which will be eligible for high-quality, low-cost versions of (the drug) for PrEP is ongoing and we will provide information as soon as details are finalised. Gilead is committed to transparency and delivering updates in a timely fashion,” said the statement.

In conclusion, the emergence of a novel twice-yearly injectable HIV prevention method, lenacapavir, marks a significant breakthrough in the fight against HIV. This innovative approach offers a much-needed respite from the pill burden associated with lifelong anti-retroviral therapy (ART). As we move forward, it is crucial that stakeholders engage with Gilead to negotiate a reduced production price, aiming to make this life-changing treatment accessible for mass production at a cost of less than US$100. By doing so, we can ensure that this groundbreaking solution reaches those who need it most, ultimately contributing to a significant reduction in new HIV infections and improved health outcomes globally.Feedback: [email protected]

The Myths and Misconceptions Fuelling New HIV Infections 
Gokwe South to establish drug rehabilitation centre 
Govt to take over Torwood hospital
Govt in witch-hunt: Psmas board
Bar-turned-clinic to benefit 10 000
Share This Article
Email Copy Link Print
Previous Article Mupamombe wins colleges’ soccer tourney
Next Article Nyaungwe Arts wins Chibuku NeShamwari
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Recipe Rating




- Advertisement -

You May also Like

HealthLocal News

Gweru residents defecate in alleys, open spaces 

14 September 2022
EducationHealth

Students, nurses call for shutdown

5 May 2022
Health

Religious beliefs trigger rise in home deliveries

24 March 2025
Health

Mutare NatPharm warehouse construction 60% complete

14 January 2023
Show More
  • More News:
  • ZANU PF
  • July Moyo
  • Emmerson Mnangagwa
  • CCC
  • Citizens Coalition for Change
  • Tendai Biti
  • Kudakwashe Dhewa
  • Nelson Chamisa
  • Zvishavane
  • ZEC
  • Douglas Mwonzora
  • Mutevekwi River
  • Winston Chitando
  • Gutsaruzhinji
  • Larry Mavima
  • Tongogara Rural District Council
  • Masvingo United
  • Chamisa
  • EMA
  • Unki Mine
Masvingo Mirror

The Independent Paper for Masvingo and the Southern Region

Youtube Medium Rss

About Company

  • About us
  • Advertise with US
  • Complaint
  • Privacy Policy
  • Cookie Policy
  • Submit a Tip
Subscribe Now for Real-time Updates on the Latest Stories!
© 2026 Masvingo Mirror. All Rights Reserved.
Welcome to Foxiz
Username or Email Address
Password

Lost your password?